W. Lee, Hepatitis B Virus Infection, New England Journal of Medicine, vol.337, issue.24, pp.1733-1745, 1997.
DOI : 10.1056/NEJM199712113372406
URL : https://hal.archives-ouvertes.fr/hal-01260424

J. Perz, G. Armstrong, L. Farrington, Y. Hutin, and B. Bell, The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide, Journal of Hepatology, vol.45, issue.4, pp.529-538, 2006.
DOI : 10.1016/j.jhep.2006.05.013

U. Iloeje, H. Yang, J. Su, C. Jen, S. You et al., Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load, Gastroenterology, vol.130, issue.3, pp.678-686, 2006.
DOI : 10.1053/j.gastro.2005.11.016

C. Chen, H. Yang, J. Su, C. Jen, S. You et al., Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level, JAMA, vol.295, issue.1, pp.65-73, 2006.
DOI : 10.1001/jama.295.1.65

T. Stroffolini, A. Mele, M. Tosti, G. Gallo, E. Balocchini et al., The impact of the hepatitis B mass immunisation campaign on the incidence and risk factors of acute hepatitis B in Italy, Journal of Hepatology, vol.33, issue.6, pp.980-985, 2000.
DOI : 10.1016/S0168-8278(00)80132-4

D. Lavanchy, Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures, Journal of Viral Hepatitis, vol.34, issue.2, pp.97-107, 2004.
DOI : 10.1056/NEJM200012073432302

M. Chang, C. Chen, M. Lai, H. Hsu, T. Wu et al., Universal Hepatitis B Vaccination in Taiwan and the Incidence of Hepatocellular Carcinoma in Children, New England Journal of Medicine, vol.336, issue.26, pp.1855-1859, 1997.
DOI : 10.1056/NEJM199706263362602

P. Marcellin, G. Lau, F. Bonino, P. Farci, S. Hadziyannis et al., Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B, New England Journal of Medicine, vol.351, issue.12, pp.1206-1217, 2004.
DOI : 10.1056/NEJMoa040431

F. Zoulim, Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic Hepatitis B virus infection, Antiviral Research, vol.64, issue.1, pp.1-15, 2004.
DOI : 10.1016/j.antiviral.2004.07.003
URL : https://hal.archives-ouvertes.fr/inserm-00136413

Y. Liaw, J. Sung, W. Chow, G. Farrell, C. Lee et al., Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease, New England Journal of Medicine, vol.351, issue.15, pp.1521-1531, 2004.
DOI : 10.1056/NEJMoa033364

V. Puro, D. Carli, G. Cicalini, S. Soldani, F. Balslev et al., European recommendations for the management of healthcare workers occupationally exposed to hepatitis B virus and hepatitis C virus, Euro Surveill, vol.10, 2005.

Y. Liaw, N. Leung, R. Guan, G. Lau, I. Merican et al., Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update, EASL International Consensus Conference on Hepatitis B. 13 Consensus statement (long version, pp.472-489, 2002.
DOI : 10.1111/j.1365-2036.2004.01845.x

H. Yang, S. Lu, Y. Liaw, S. You, C. Sun et al., Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma, New England Journal of Medicine, vol.347, issue.3, pp.168-174, 2002.
DOI : 10.1056/NEJMoa013215

G. Realdi, G. Fattovich, S. Hadzyiannis, S. Schalm, P. Almasio et al., Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study, Journal of Hepatology, vol.21, issue.4, pp.656-6661225, 1994.
DOI : 10.1016/S0168-8278(94)80115-0

H. Janssen, M. Van-zonneveld, H. Senturk, S. Zeuzem, U. Akarca et al., Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial, The Lancet, vol.365, issue.9454, pp.123-129, 2005.
DOI : 10.1016/S0140-6736(05)17701-0

C. Lai, R. Chine, N. Leung, T. Chang, R. Guan et al., A One-Year Trial of Lamivudine for Chronic Hepatitis B, New England Journal of Medicine, vol.339, issue.2, pp.61-68, 1998.
DOI : 10.1056/NEJM199807093390201

F. Zoulim, J. Dienstag, R. Goldin, E. Heathcote, H. Hann et al., A preliminary benefit-risk assessment of Lamivudine for the treatment of chronic hepatitis B virus infection Histological outcome during long-term lamivudine therapy Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy al. e. A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine, Drug Saf Gastroenterology Hepatology J Viral Hepat, vol.2512433, issue.27, pp.497-510105, 2001.

C. Lai, J. Dienstag, E. Schiff, N. Leung, M. Atkins et al., Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B Long-term safety of lamivudine treatment in patients with chronic hepatitis B Efficacy of longterm lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B, Clin Infect Dis Gastroenterology Hepatology Hepatology, vol.361253232, issue.31, pp.687-6961714, 2000.

P. Lampertico, M. Vigano, E. Manenti, M. Iavarone, G. Lunghi et al., Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine, Hepatology, vol.126, issue.6, pp.1414-1419, 2005.
DOI : 10.1002/hep.20939

T. Chang, R. Gish, R. De-man, A. Gadano, J. Sollano et al., A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B, New England Journal of Medicine, vol.354, issue.10, pp.1011-10201001, 2006.
DOI : 10.1056/NEJMoa051285

F. Zoulim, R. Entecavir-gish, T. Chang, D. Man, R. et al., A new treatment option for chronic hepatitis B Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in HBeAg(+) chronic hepatitis B patients, J Clin Virol Hepatology, vol.3942, issue.suppl1, p.181, 2005.

R. Rose, S. Levine, J. Baldick, K. Pokornowski, M. Plym et al., Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine Entecavir two year resistance update: no resistance observed in nucleoside naive patients and low frequency resistance emergence in lamivudine refractory patients, Antimicrob Agents Chemother Hepatology, vol.4842, issue.suppl1, pp.3498-3507, 2004.

F. Zoulim, D. Tenney, R. Rose, C. Baldick, S. Levine et al., Hepatitis B virus resistance to entecavir in nucleoside na??ve patients: Does it exist?, Hepatology, vol.55, issue.6, pp.1404-1407, 2006.
DOI : 10.1002/hep.21451

C. Lai, S. Lim, N. Brown, X. Zhou, D. Lloyd et al., A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection, Hepatology, vol.5, issue.3, pp.719-726, 2004.
DOI : 10.1002/hep.20374

C. Lai, E. Gane, and Y. Liaw, Telbivudine versus lamivudine for chronic hepatitis B: first year results from the interantional phase III globe trial, Hepatology, vol.42, pp.748-795, 2005.

C. Lai, N. Leung, E. Teo, M. Tong, F. Wong et al., A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus, Gastroenterology Clin Infect Dis N Engl J Med, vol.12939348, issue.48, pp.528-5361062, 2003.

K. Lacombe, J. Gozlan, P. Boelle, L. Serfaty, F. Zoulim et al., Long-term hepatitis B virus dynamics in HIV???hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate, AIDS, vol.19, issue.9, pp.907-915, 2005.
DOI : 10.1097/01.aids.0000171404.07995.5c

G. Dore, D. Cooper, A. Pozniak, E. Dejesus, L. Zhong et al., Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection, J Infect Dis Hepatology Peters MG, vol.18940, issue.52, pp.1185-11921421, 2004.

R. Gish, H. Trinh, N. Leung, F. Chan, M. Fried et al., Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127 Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a twoyear study, Hepatology J Hepatol, vol.4443, issue.54, pp.1110-111660, 2005.

P. Marcellin, H. Mommeja-marin, S. Sacks, G. Lau, D. Sereni et al., A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B, Hepatology, vol.75, issue.1, pp.140-148, 2004.
DOI : 10.1002/hep.20257

. Antiviral-activity-of-clevudine, -fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax), Hepatology, vol.33, issue.12, pp.254-266, 2001.

A. Jacquard, M. Nassal, C. Pichoud, S. Ren, U. Schultz et al., Effect of a combination of clevudine and emtricitabine with adenovirus-mediated delivery of gamma interferon in the woodchuck model of hepatitis B virus infection Pharmacokinetics of pradefovir and PMEA in healthy volunteers after oral dosing of pradefovir, Antimicrob Agents Chemother J Clin Pharmacol, vol.4845, issue.58, pp.2683-26921250, 2004.

E. Keeffe, P. Marcellin, N. Tassopoulos, R. Volpes, G. Pastore et al., 60. Gish RG Clinical trial results of new therapies for HBV: implications for treatment guidelines Efficacy of lamivudine in patients with hepatitis B e antigen-Negative/Hepatitis B virus DNApositive (Precore mutant) chronic hepatitis B [In Process Citation], Clin Gastroenterol Hepatol Semin Liver Dis Hepatology J Hepatol, vol.252942, issue.62, pp.29-39889, 1999.

D. Marco, V. Marzano, A. Lampertico, P. Andreone, P. Santantonio et al., Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine, Hepatology, vol.348, issue.4, pp.883-891, 2004.
DOI : 10.1002/hep.20381

M. Rizzetto, G. Papatheodoridis, E. Dimou, A. Laras, V. Papadimitropoulos et al., Efficacy of lamivudine in HBeAg-negative chronic hepatitis B Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease, J Med Virol Hepatology, vol.6636, issue.65, pp.435-451219, 2002.

M. Buti, M. Cotrina, R. Jardi, E. De-castro, F. Rodriguez-frias et al., Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B, Journal of Viral Hepatitis, vol.22, issue.4, pp.270-275, 2001.
DOI : 10.1053/jhep.2000.19622

S. Hadziyannis, N. Tassopoulos, E. Heathcote, T. Chang, G. Kitis et al., Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen???Negative Chronic Hepatitis B, New England Journal of Medicine, vol.348, issue.9, pp.800-807, 2003.
DOI : 10.1056/NEJMoa021812

S. Hadziyannis, N. Tassopoulos, E. Heathcote, T. Chang, G. Kitis et al., Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B, New England Journal of Medicine, vol.352, issue.26, pp.2673-2681, 2005.
DOI : 10.1056/NEJMoa042957

S. Hadziyannis, N. Tassopoulos, E. Heathcote, T. Chang, G. Kitis et al., Long-Term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, Gastroenterology Hepatology, vol.7034, pp.411-416, 2001.

R. Leduc, Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B, Hepatology, vol.31, pp.207-210, 2000.

J. Vierling, Management of HBV Infection in Liver Transplantation Patients, International Journal of Medical Sciences, vol.2, pp.41-49, 2005.
DOI : 10.7150/ijms.2.41

G. Dore, R. Guan, W. Jafri, S. Sarin, S. Keeffe et al., Management of chronic hepatitis B in challenging patient populations, Liver International, vol.26, issue.S2, pp.38-46, 2006.
DOI : 10.1111/j.1478-3231.2006.01375.x

F. Zoulim, Antiviral therapy of chronic hepatitis B, Antiviral Research, vol.71, issue.2-3, pp.206-215, 2006.
DOI : 10.1016/j.antiviral.2006.04.003
URL : https://hal.archives-ouvertes.fr/inserm-00134589

F. Zoulim, R. Perrillo, H. Hann, D. Mutimer, B. Willems et al., Antiviral therapy of chronic hepatitis B, Antiviral Research, vol.71, issue.2-3, pp.299-30581, 2004.
DOI : 10.1016/j.antiviral.2006.04.003
URL : https://hal.archives-ouvertes.fr/inserm-00134589

P. Lampertico, A. Marzano, M. Levrero, T. Santantonio, D. Marco et al., Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic hepatitis BAbstract LB5, p693A 81 A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients Stepwise process for the development of entecavir resistance in a chronic Hepatitis B virus infected patient, Hepatology Gastroenterology J Hepatol, vol.44129, issue.83, pp.1198-1209, 2005.

P. Angus, R. Vaughan, S. Xiong, H. Yang, W. Delaney et al., Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase, Gastroenterology, vol.125, issue.2, pp.292-297, 2003.
DOI : 10.1016/S0016-5085(03)00939-9

M. Brunelle, A. Jacquard, C. Pichoud, D. Durantel, S. Carrouee-durantel et al., Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir, Hepatology, vol.64, issue.6, pp.1391-1398, 2005.
DOI : 10.1002/hep.20723
URL : https://hal.archives-ouvertes.fr/inserm-00133179

S. Villet, A. Ollivet, C. Pichoud, L. Barraud, J. Villeneuve et al., Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient, Journal of Hepatology, vol.46, issue.3, pp.531-538, 2007.
DOI : 10.1016/j.jhep.2006.11.016
URL : https://hal.archives-ouvertes.fr/inserm-00133115

S. Villet, C. Pichoud, J. Villeneuve, C. Trepo, and F. Zoulim, Selection of a Multiple Drug-Resistant Hepatitis B Virus Strain in a Liver-Transplanted Patient, Gastroenterology, vol.131, issue.4, pp.1253-1261, 2006.
DOI : 10.1053/j.gastro.2006.08.013
URL : https://hal.archives-ouvertes.fr/inserm-00133169

F. Zoulim, A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus, Hepatology, vol.40, pp.855-864, 2004.
URL : https://hal.archives-ouvertes.fr/inserm-00137151

C. Lai, R. Chien, N. Leung, T. Chang, R. Guan et al., A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature, N Engl J Med Hepatology, vol.33937, issue.92, pp.61-681309, 1998.

T. Poynard, F. Zoulim, V. Ratziu, F. Degos, F. Imbert-bismut et al., Telbivudine globe trial: maximal early HBV suppression id predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patientsAbstract 112, p230A. 94 Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection, Hepatology Am J Gastroenterol Microbiol Mol Biol Rev, vol.4410064, pp.1970-198051, 2000.

D. Ganem, A. Prince, B. Seigneres, C. Pichoud, P. Martin et al., Hepatitis B virus infection--natural history and clinical consequences Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses, N Engl J Med Hepatology, vol.35036, issue.97, pp.1118-1129710, 2002.

G. Moraleda, J. Saputelli, C. Aldrich, D. Averett, L. Condreay et al., Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus, J. Virol, vol.71, pp.9392-9399, 1997.

A. Jacquard, M. Brunelle, C. Pichoud, D. Durantel, S. Carrouee-durantel et al., In Vitro Characterization of the Anti-Hepatitis B Virus Activity and Cross-Resistance Profile of 2',3'-Dideoxy-3'-Fluoroguanosine, Antimicrobial Agents and Chemotherapy, vol.50, issue.3, pp.955-961, 2006.
DOI : 10.1128/AAC.50.3.955-961.2006
URL : https://hal.archives-ouvertes.fr/inserm-00134592

S. Urban and P. Gripon, Inhibition of Duck Hepatitis B Virus Infection by a Myristoylated Pre-S Peptide of the Large Viral Surface Protein, Journal of Virology, vol.76, issue.4, pp.1986-1990, 2002.
DOI : 10.1128/JVI.76.4.1986-1990.2002

D. Wet, R. Edwards, D. Colledge, T. Shaw, P. Furman et al., Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudineresistant strains of hepatitis B virus in vitro, Antimicrob Agents Chemother, vol.46, pp.3057-3060, 2002.

K. Deres, C. Schroder, A. Paessens, S. Goldmann, H. Hacker et al., Inhibition of Hepatitis B Virus Replication by Drug-Induced Depletion of Nucleocapsids, Science, vol.299, issue.5608, pp.893-896, 2003.
DOI : 10.1126/science.1077215

T. Block, X. Lu, A. Mehta, B. Blumberg, B. Tennant et al., Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking, Nature Medicine, vol.6, issue.5, pp.610-614, 1998.
DOI : 10.1038/40677

F. Zoulim, New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA, Journal of Hepatology, vol.42, issue.3, pp.302-308, 2005.
DOI : 10.1016/j.jhep.2004.12.015

J. Tuttleman, C. Pourcel, and J. Summers, Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells, Cell, vol.47, issue.3, pp.451-460, 1986.
DOI : 10.1016/0092-8674(86)90602-1

B. Werle-lapostolle, S. Bowden, S. Locarnini, K. Wursthorn, J. Petersen et al., Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy1 ???, Gastroenterology, vol.126, issue.7, pp.1750-1758, 2004.
DOI : 10.1053/j.gastro.2004.03.018

A. Bertoletti and N. Naoumov, Translation of immunological knowledge into better treatments of chronic hepatitis B, Journal of Hepatology, vol.39, issue.1, pp.115-124, 2003.
DOI : 10.1016/S0168-8278(03)00126-0

G. Webster, S. Reignat, D. Brown, G. Ogg, L. Jones et al., Longitudinal Analysis of CD8+ T Cells Specific for Structural and Nonstructural Hepatitis B Virus Proteins in Patients with Chronic Hepatitis B: Implications for Immunotherapy, Journal of Virology, vol.78, issue.11, pp.5707-5719, 2004.
DOI : 10.1128/JVI.78.11.5707-5719.2004

A. Penna, M. Artini, A. Cavalli, M. Levrero, A. Bertoletti et al., Long-lasting memory T cell responses following self-limited acute hepatitis B., Journal of Clinical Investigation, vol.98, issue.5, pp.1185-1194, 1996.
DOI : 10.1172/JCI118902

A. Gehring, D. Sun, P. Kennedy, E. Nolte-'t-hoen, S. Lim et al., The Level of Viral Antigen Presented by Hepatocytes Influences CD8 T-Cell Function, Journal of Virology, vol.81, issue.6, pp.2940-2949, 2007.
DOI : 10.1128/JVI.02415-06

L. Guidotti, R. Rochford, J. Chung, M. Shapiro, R. Purcell et al., Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection, Science, vol.284, issue.5415, pp.825-829, 1999.
DOI : 10.1126/science.284.5415.825

V. Cavanaugh, L. Guidotti, and F. Chisari, Interleukine-12 inhibits hepatitis B virus replication in transgenic mice, J. Virol, vol.71, pp.3236-3243, 1997.

S. Wieland, H. Spangenberg, R. Thimme, R. Purcell, and F. Chisari, Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees, Proceedings of the National Academy of Sciences, vol.101, issue.7, pp.2129-2134, 2004.
DOI : 10.1073/pnas.0308478100

I. Fourel, J. Cullen, J. Saputelli, C. Aldrich, P. Schaffer et al., Evidence that hepatocyte turnover is required for rapid clearance of Duck Hepatitis B Virus during antiviral therapy of chronically infected ducks, J. Virol, vol.68, pp.8321-8330, 1994.

J. Guo, H. Zhou, C. Liu, C. Aldrich, J. Saputelli et al., Apoptosis and Regeneration of Hepatocytes during Recovery from Transient Hepadnavirus Infections, Journal of Virology, vol.74, issue.3, pp.1495-1505, 2000.
DOI : 10.1128/JVI.74.3.1495-1505.2000

J. Summers, A. Jilbert, Y. W. Aldrich, C. Saputelli, J. Litwin et al., Hepatocyte turnover during resolution of a transient hepadnaviral infection, Proceedings of the National Academy of Sciences, vol.100, issue.20, pp.11652-11659, 2003.
DOI : 10.1073/pnas.1635109100

J. Summers and W. Mason, Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy, Proceedings of the National Academy of Sciences, vol.101, issue.2, pp.638-640, 2004.
DOI : 10.1073/pnas.0307422100
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC327200

B. Rehermann, C. Ferrari, C. Pasquinelli, and F. Chisari, The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T???lymphocyte response, Nature Medicine, vol.66, issue.10, pp.1104-1108, 1996.
DOI : 10.1016/0022-1759(79)90239-4

S. Menne, C. Roneker, B. Korba, J. Gerin, B. Tennant et al., Immunization with Surface Antigen Vaccine Alone and after Treatment with 1-(2-Fluoro-5-Methyl-??-L-Arabinofuranosyl)-Uracil (L-FMAU) Breaks Humoral and Cell-Mediated Immune Tolerance in Chronic Woodchuck Hepatitis Virus Infection, Journal of Virology, vol.76, issue.11, pp.5305-5314, 2002.
DOI : 10.1128/JVI.76.11.5305-5314.2002

C. Rollier, C. Sunyach, L. Barraud, N. Madani, C. Jamard et al., Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein, Gastroenterology, vol.116, issue.3, pp.658-665, 1999.
DOI : 10.1016/S0016-5085(99)70188-5

M. Mancini, M. Hadchouel, P. Tiollais, and M. Michel, Regulation of hepatitis B virus mRNA expression in a hepatitis B surface antigen transgenic mouse model by IFN-gamma-secreting T cells after DNA-based immunization, J Immunol, vol.161, pp.5564-5570, 1998.

M. Lu, B. Lohrengel, G. Hilken, T. Kemper, and M. Roggendorf, Woodchuck Gamma Interferon Upregulates Major Histocompatibility Complex Class I Transcription but Is Unable To Deplete Woodchuck Hepatitis Virus Replication Intermediates and RNAs in Persistently Infected Woodchuck Primary Hepatocytes, Journal of Virology, vol.76, issue.1, pp.58-67, 2002.
DOI : 10.1128/JVI.76.1.58-67.2002

J. Wang, S. Gujar, L. Cova, and T. Michalak, Bicistronic Woodchuck Hepatitis Virus Core and Gamma Interferon DNA Vaccine Can Protect from Hepatitis but Does Not Elicit Sterilizing Antiviral Immunity, Journal of Virology, vol.81, issue.2, pp.903-916, 2007.
DOI : 10.1128/JVI.01537-06
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1797430

F. Siegel, M. Lu, and M. Roggendorf, Coadministration of Gamma Interferon with DNA Vaccine Expressing Woodchuck Hepatitis Virus (WHV) Core Antigen Enhances the Specific Immune Response and Protects against WHV Infection, Journal of Virology, vol.75, issue.11, pp.5036-5042, 2001.
DOI : 10.1128/JVI.75.11.5036-5042.2001

W. Lewis, E. Levine, B. Griniuvene, K. Tankersley, J. Colacino et al., Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts., Proc. Natl. Acad. Sci, pp.3592-3597, 1996.
DOI : 10.1073/pnas.93.8.3592

R. Colonno, R. Rose, S. Levine, J. Baldick, K. Pokornowski et al., Entecavir two year resistance update: no resistance observed in nucleoside naive patients and low frequency resistance emergence in lamivudine refractory patients, Hepatology, vol.42, p.573, 2005.

F. Zoulim, In Vitro Models for Studying Hepatitis B Virus Drug Resistance, Seminars in Liver Disease, vol.26, issue.2, pp.171-180, 2006.
DOI : 10.1055/s-2006-939759

H. Yang, C. Westland, S. Xiong, and W. Delaney, In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector, Antiviral Research, vol.61, issue.1, pp.27-36, 2004.
DOI : 10.1016/j.antiviral.2003.07.003

H. Yang, X. Qi, A. Sabogal, M. Miller, S. Xiong et al., Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV, Antivir Ther, vol.10, pp.625-633, 2005.

D. Wet, A. Ray, H. Yang, X. Qi, S. Xiong et al., Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus, Antimicrob Agents Chemother, vol.50, pp.2471-2477, 2006.